1-4 of 4
Wahib S. Ead
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy

Free
Elizabeth Budde, Jason Westin, Huilai Zhang, Dai Maruyama, Eduardo M. Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam Olszewski, Joan Ashby, Shen Yin, Wahib S. Ead, Martin Janousek, Song Pham, Connie L. Batlevi, Michael C. Wei, Won-Seog Kim
Journal: Blood
Blood (2025) 146 (Supplement 1): 5509.
https://doi.org/10.1182/blood-2025-5509
Published: 2025
Journal Articles

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Free
Nilanjan Ghosh, Julio Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam Olszewski, Seema Naik, Song Pham, Michael C. Wei, Connie L. Batlevi, Iris To, Wahib S. Ead, Sneha Makadia, Elicia Peneul, Elizabeth Budde
Journal: Blood
Blood (2025) 146 (Supplement 1): 1020.
https://doi.org/10.1182/blood-2025-1020
Published: 2025
Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Free
Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde
Journal: Blood
Blood (2025) 146 (Supplement 1): 3735.
https://doi.org/10.1182/blood-2025-3735
Published: 2025
Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Free
Julio C. Chavez, Adam J. Olszewski, Mariana Bastos-Oreiro, Sarit E. Assouline, Izidore S. Lossos, Catherine Diefenbach, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Nirav N. Shah, Ronan Foley, Daniel J Hodson, Sneha Makadia, Song Pham, Elicia Penuel, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 989.
https://doi.org/10.1182/blood-2024-194581
Published: 2024